報價延遲最少15分鐘:2026/04/23 04:22 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.54
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.79/-1.02
|
|
企業價值
33.05M
|
| 資產負債 |
|
每股賬面淨值
1.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
3.55M
|
|
每股收益
0.54
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphomaand pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS). |
